DrugPatentWatch Database Preview
Cppi Cv Company Profile
What is the competitive landscape for CPPI CV, and what generic alternatives to CPPI CV drugs are available?
CPPI CV has one approved drug.
There are three US patents protecting CPPI CV drugs.
There are seventy-four patent family members on CPPI CV drugs in forty-one countries and twenty-seven supplementary protection certificates in fourteen countries.
Summary for Cppi Cv
| International Patents: | 74 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Cppi Cv
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-003 | Jan 26, 2006 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-001 | Jan 26, 2006 | RX | Yes | No | Start Trial | Start Trial | |||||
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-001 | Jan 26, 2006 | RX | Yes | No | 7,211,600*PED | Start Trial | Y | Start Trial | |||
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-004 | Mar 31, 2009 | RX | Yes | No | 7,211,600*PED | Start Trial | Y | Start Trial | |||
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-002 | Jan 26, 2006 | RX | Yes | No | 6,573,293*PED | Start Trial | Y | Start Trial | |||
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-001 | Jan 26, 2006 | RX | Yes | No | 7,125,905*PED | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for CPPI CV drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 12.5 mg, 25 mg, 37.5 mg and 50 mg | ➤ Subscribe | 2010-01-26 |
International Patents for Cppi Cv Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Germany | 122008000002 | Start Trial |
| Denmark | 1255536 | Start Trial |
| Bulgaria | 107078 | Start Trial |
| Mexico | PA02008021 | Start Trial |
| Yugoslavia | 61402 | Start Trial |
| Hong Kong | 1051188 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cppi Cv Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1255752 | 378 | Finland | Start Trial | |
| 1255752 | SPC004/2008 | Ireland | Start Trial | SPC004/2008: 20081105, EXPIRES: 20210718 |
| 1255752 | 300332 | Netherlands | Start Trial | PRODUCT NAME: SUNITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET L-MALAATZOUT; REGISTRATION NO/DATE: EU/1/06/347/001-003 20060724 |
| 1255752 | 2008/004 | Ireland | Start Trial | PRODUCT NAME: SUNITINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE L-MALATE SALT; AUTHORISATION NO/DATE: IRELAND EU/1/06/347/001, EU/1/06/347/002, EU/1/06/347/003 20060719 |
| 1255752 | SPC003/2010 | Ireland | Start Trial | SPC003/2010: 20100702, EXPIRES: 20240922 |
| 1255752 | 08C0002 | France | Start Trial | PRODUCT NAME: SUNITINIB MALATE; REGISTRATION NO/DATE: EU/1/06/347/001 20060724 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
